anxiety relief: nootropics and compounds | sci-wiki

Amibegron

Amibegron approached depression and anxiety from a genuinely unusual angle, agonizing the atypical beta-3 adrenergic receptor rather than touching serotonin transporters or GABA-A directly, on preclinical evidence that beta-3 stimulation increased serotonin and tryptophan levels and blunted stress-induced behavioral changes in rodents. Sanofi-Aventis pushed it all the way to worldwide Phase III trials for both depression and generalized anxiety disorder, a serious late-stage bet on a first-in-class mechanism. The trials came back unconvincing on efficacy, and Sanofi discontinued the program in 2008, leaving beta-3 adrenergic agonism as one of the more interesting mechanistic roads not taken in modern psychopharmacology.

reference

Serotonergic

Deramciclane

Deramciclane came out of EGIS Pharmaceuticals in Hungary as a non-benzodiazepine anxiolytic working through 5-HT2A/2C receptors instead of GABA-A, and Orion Pharma partnered on it to run one of the largest clinical programs in Orion's 20-year research history. Early dose-finding data in generalized anxiety disorder actually looked encouraging; the 60 mg/day arm cleared the psychic-anxiety subscale of the HAM-A against placebo. That promise collapsed when the larger Phase III studies read out; Orion announced in 2003 that deramciclane simply lacked sufficient efficacy in GAD, closing out a program that had consumed years of investment on a hopeful mechanistic bet.

reference

Serotonergic

Gepirone

Gepirone spent more than two decades in regulatory purgatory before it ever reached a pharmacy shelf, and its story is really about how brutal the FDA approval bar can be even for a drug that eventually worked. Fabre-Kramer Pharmaceuticals (with Organon as an early partner) submitted gepirone for depression in the late 1990s and got rejected in 1999, then again after resubmission in 2001, again in 2003 to 2004, and a fourth time in 2007, each rejection hinging on inconsistent trial results even as some studies showed real separation from placebo. The company kept the compound alive through a formal dispute appeal granted in 2016, and the FDA finally approved gepirone extended-release as Exxua for major depressive disorder in September 2023, an almost 25-year odyssey from first submission to market. It is less a lost drug than a drug that got found again, after nearly disappearing for good.

reference

Serotonergic

Tandospirone

Tandospirone is a case of a drug that succeeded, just never where most of the archive's audience would notice; the azapirone was approved and marketed in Japan in 1996 as Sediel for generalized anxiety disorder, and later in China in 2004, where it remains in clinical use today for anxiety and, off-label, mood and psychotic-adjunct indications. It never sought FDA approval and stayed almost entirely off the radar in the US and Europe, overshadowed first by benzodiazepines and later by SSRIs. Its main pharmacological claim to fame is being one of the most selective 5-HT1A partial agonists among the azapirones, with comparatively little dopamine D2 or off-target receptor activity compared to relatives like buspirone.

reference